Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Risk and Volatility
Sarepta Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.
Profitability
This table compares Sarepta Therapeutics and AbCellera Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sarepta Therapeutics | -13.48% | -1.60% | -0.66% |
| AbCellera Biologics | -248.83% | -17.49% | -12.36% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sarepta Therapeutics | 7 | 7 | 7 | 0 | 2.00 |
| AbCellera Biologics | 1 | 2 | 5 | 1 | 2.67 |
Sarepta Therapeutics presently has a consensus price target of $22.71, indicating a potential upside of 31.01%. AbCellera Biologics has a consensus price target of $13.38, indicating a potential downside of 1.22%. Given Sarepta Therapeutics’ higher possible upside, equities analysts plainly believe Sarepta Therapeutics is more favorable than AbCellera Biologics.
Insider and Institutional Ownership
86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Sarepta Therapeutics and AbCellera Biologics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sarepta Therapeutics | $2.20 billion | 0.83 | -$713.41 million | ($2.90) | -5.98 |
| AbCellera Biologics | $66.17 million | 62.74 | -$146.41 million | ($0.54) | -25.07 |
AbCellera Biologics has lower revenue, but higher earnings than Sarepta Therapeutics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Sarepta Therapeutics beats AbCellera Biologics on 8 of the 15 factors compared between the two stocks.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
About AbCellera Biologics
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
